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Abstract
According to the McKnight Brain Institute, at least 10,000 people annually in the USA suffer from
a central nervous system (CNS) injury. These injuries can cause serve disabilities including
paralysis. Due to the complexity of the spinal cord, it is common that potential CNS treatments are
first applied to an optic nerve crush (ONC) model in rats. Two proposed treatments were
employed; one where nerve growth factor (NGF) was immobilized to a chitosan substrate to
stimulate axonal regeneration, and the other using pentadecafluorooctanoyl chloride modified
methacrylamide chitosan (MAC(Ali15)F) hydrogel to enhance local oxygenation. The two
different treatments were formed into wraps and directly applied to the ONC. The treatments were
evaluated using behavioral analysis and immunohistochemistry. There was no significant
difference between the treatment and control groups due to flaws in the material and surgical
procedures. The crush was only confirmed in 38% of the rats. Also, the NGF released from the
material was considerably lower than similar published studies. In addition, the MAC(Ali15)F was
used in such a small amount and was not loaded with oxygen prior to use. Despite the failure of
this study, the possibilities for future work with biomaterial based CNS injury treatments have
been highlighted.
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Executive Summary
According to the McKnight Brain Institute at the University of Florida, at least 10,000
people per year in the United States alone suffer from a central nervous system (CNS) injury.
These types of injuries in the worst cases can cause serve disabilities including paralysis. Due to
the complexity of the spinal cord, it is common that potential CNS treatments are first applied to
an optic nerve model. The optic nerve is a bundle of continuous axons that extend from the retina
of the eye to the brain to pass on visual information. Because all of the axons start and stop in the
same place, it is simpler to trace the axons and analyze their regeneration after injury then in the
spinal cord. In the optic nerve crush (ONC) model, the optic nerve is exposed and subjected to a
mild crush and some axons are damaged, without completely severing the optic nerve. This model
has been used numerous times to study axon regeneration treatments.
Two proposed treatments for an ONC injury were employed in this study. One where nerve
growth factor (NGF) was immobilized to a chitosan substrate to stimulate axonal regeneration.
The other using pentadecafluorooctanoyl chloride modified methacrylamide chitosan
(MAC(Ali15)F) hydrogel to reduce damage from reactive oxygen species and enhance local
oxygenation. The two different treatments were formed into tubes or wraps that were directly
applied to the optic nerve after injury in male Sprague Dawley rats. The treatments were evaluated
using behavioral analysis and immunohistochemistry (IHC). There was no significant and
consistent trend in the behavioral analysis. The IHC reviled that there was a significant difference
between the uninjured optic nerves and the ones that received the ONC injury, but there was no
difference between the groups that received a treatment and the ones that did not. It was a
concluded that an injury did occur, but was not consistent or sever enough to test the efficacy of
the different treatments.
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The inconclusive results of this study are most likely due to flaws in the material design
and the surgical procedures. The crush was only visually confirmed on 38% of the rats that
received the injury, so it was not consistent across all the groups. Also, the nerve growth factor
released from the material used in this study was orders of magnitude lower than similar published
studies. In addition, the fluorinated chitosan was used in such a small amount that in order to
observe an effect, more material would be required. Even though this preliminary study was not
successful, much was learned about the optic nerve crush model and how these types of treatments
could be applied. For example, since the immobilized protein by itself was not sufficient, it could
be coupled with soluble proteins or additional neural growth stimulants to better treat the injury.
Overall, even though this novel approach to the treatment of an ONC injury was not initially
successful, none of the results indicated that using a biomaterial-based wrap is not a viable
treatment idea. This study highlights the possibilities for future work with biomaterial-based
central nervous system injury treatments.
Through this study many different analytical techniques were used. Skills is experimental
planning, biomaterial synthesis, cell culture, handling animals, surgical and dissection procedures,
tissue preparation and analysis, immunohistochemistry, image analysis, and statistical analysis
were gained. This study took a lot of planning and coordination between multiple parties which
was excellent preparation for a full-time career in any engineering field. This type of animal study
was new to the Leipzig group. It was incredibly beneficial to work with NEOMED to leverage
their expertise; however nothing beats personal experience. My advice to future students taking on
this complex of a study in the future is to not be discouraged by failure, but to push on and learn
from the mistakes made so the next round can be more successful.
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Introduction
According to the McKnight Brain Institute at the University of Florida, at least 10,000
people per year in the United States alone suffer from a central nervous system (CNS) injury.
These types of injuries in the worst cases can cause serve disabilities including paralysis. Due to
the complexity of the spinal cord, it is common that potential CNS treatments are first applied to
an optic nerve model. The purpose is of this project is to test the effects of nerve growth factor
(NGF) sustained delivery to retinal ganglion cells (RGCs) after an optic nerve crush (ONC) was
performed in vivo. A chitosan tube was prepared, and then biotinylated NGF (bNGF) was
immobilized on the surface of the inside of the tube. For the ONC model, male Sprague Dawley
rats were used. Through IACUC approved surgical procedures, the optic nerve of the right eye was
exposed, a mild crush was administered using a micro-vascular clip, and then the chitosan tube
was placed around the crush site and fibrin glue was used to hold the tube in place. The rats were
observed over 21 days after the procedure. At day 18, a fluorescent marker was intravitreally
injected. This marker traveled through the optic nerve and into the brain so the effectiveness of the
treatment could be evaluated. In addition to immobilized NGF, crush sites were treated using
fluorinated methacrylamide chitosan (MAC(Ali15)F), which is a fluorinated chitosan based
material used to sequester and deliver oxygen from the environment to an injury site. This material
has been investigated for wound healing application to provide additional oxygen to encourage
healing. In this case, it was used to determine if it would also promote a good growing environment
for the optic nerve crush.
Five different test groups were used in this experiment: No treatment (left eye), Crush,
Chitosan Tube, immobilized NGF (ImmbNGF) and MAC(Ali15)F. The injuries and treatments
were applied to the right eye of each rat. The left eye was used as a no treatment control group.
The crush group had the injury applied, but no treatment. The chitosan group had the injury applied
and will be treated with a chitosan tube without immobilized NFG. The ImmbNGF group had the
injury applied and the chitosan with immobilized NFG applied to the crush site. The MAC(Ali15)F
group had the injury applied and the MAC(Ali15)F tube applied.
Background
Retinal ganglion cells (RGCs) are a type of neuron associated with the retina of the eye
that contains photoreceptors used to pass visual information to the brain. All types of RGCs have
a long axon that extends from the retina to the brain, which in total make up the optic nerve (Lemke
et. al., 2005; Oster et. al., 2004). RGCs can be damaged by compression of the optic nerve, which
can be caused by glaucoma, malignancy, infection, and inflammation. This can cause retraction of
axons, which will reduce the number of connections to the brain, leading to permanent damage to
the ocular system (Chang et. al. 2012; Weber et. al., 2000). Loss of vision due to the lack of
regeneration of the axon after injury is attributed to increases in reactive oxygen species, down
regulation of neurotrophins, axonal transport failure and loss of electrical activity (Chang et. al.
2012). RGC death, and permanent vision loss may be prevented be targeting RGC axon growth
and regeneration soon after injury, before RGCs are fully compromised (Berkelaar et. al., 1994;
Chrish et. al., 2010). Traditional treatments involve intravitreal injections of pharmacological
agents, which are mainly used as protective measures and do not directly address axon retraction
(Chang et. al., 2012; Hoyng et. al., 2000). Soluble guidance molecules, such as NGF, have been
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shown to promote axon growth in vitro, and to slow axonal degeneration in the early stages of
glaucoma (Chang et. al., 2012; Lambiase et. al., 2009; Shi et. al., 2007; Zhang et. al., 2011). When
these trophic factors are delivered in a soluble from, their effects are often short lived, thus there
is a need for a sustained release of these factors. This could be done using a biomaterial with an
immobilized trophic factor. MAC(Ali15)F has been previously studied in wound healing
applications in the Leipzig Lab because of the fluorine groups ability to sequester oxygen from the
environment and deliver it to a would site. It is thought that if additional oxygen is delivered to
the crush site it will provide additional energy to spare axons; furthermore, MACF may provide
the added benefit of reducing the damage inflicted by reactive oxygen species (Patil et. al., 2017).
In addition, chitosan based materials like MAC(Ali15)F have been shown to have hemostatic and
antibacterial properties as well (Pusateri et. al., 2003). These factors combined could potentially
improve the healing environment around the crush site.
Understanding RGC injuries and axon regeneration can aid in the development of a
biomaterial-based strategy that can be used as a base for the treatment of other CNS injuries and
diseases. For this reason, the optic nerve crush model was chosen to investigate the effectiveness
of a biomaterial treatment for CNS injuries.
Experimental Methods
Treatment Material Development
bNGF was be expressed, isolated and purified according to McCormick et. al. (2014). The
chitosan tubes were made by dissolving chitosan in 2 V/V% acetic acid. The chitosan solution and
100% ethanol in a 1:1 ratio were stirred from 30 minutes. Then acetic anhydride was added, then
after stirring for 10 seconds, the solution was drawn up into a syringe and injected into the tube
mold (Figure 1). The mold was set up right and the chitosan solution was left to dry for 24 hours.
Then the tube was washed using deionized water for an additional 24 hours. The tube was then be
boiled for 4 hours in 40wt% NaOH so that deacetylation will occur. Then the tube was washed
with deionized water for another 24 hours. Then the tube was cut into 2 mm pieces and sterilized
with 70% ethanol for 30 minutes. The tubes were placed upright and the bNGF was immobilized
to the inner surface according to the procedures in McCormick et. al (2013). A protein release
study was performed in 0.1M PBS and evaluated using a bNGF rat ELISA kit over 21 days.
The MAC(Ali15)F was prepared according to Wijekoon et. al. 2012. The MAC(Ali15)F
was formed into tubes in the same manner as the chitosan tubes.
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Figure 1: Figure 1 summarizes the treatment material development, the optic nerve crush injury
and treatment method, and the RGC labeling technique used for this experiment. 1. Shows the
mold used to create the chitosan/MAC(Ali15)F tubes. 2. shows the completed tube. 3. Shows the
immobilization of NGF on the chitosan tube for the ImmbNGF group. The optic nerve crush model
is shown as the final stage of the experiment. The model was implemented by inflicting the crush
injury using a micro-vascular clip, then applying the designated treatment to the injured area,, then
the axons in the RGCs were labeled using cholera toxin B (CTB) conjugated with a fluorescent
tag so the extent axonal injury and regeneration could be observed. (McCormick, 2014).
Behavioral Analysis
After the surgeries, the rats were evaluated using cage drop testing. This test was developed
with help from Dr. Denise Inman at the Northeast Ohio Medical University. The theory is that if a
rat is suspended above a cage lid by the tail, when it is able to see the surface, it will instinctively
reach toward it. The height at which the rat recognizes the surface should correlate to its visual
acuity. With the nonsurgical eye covered, the rat was raised by its tail 15cm above the cage lid,
then lowered slowly toward the cage. A ruler in the background was used to determine the height
at which the rat reaches toward the cage. A camera was used to record each trial. An observer that
was blind to the study will record the distance at which the rat reaches for the cage. Each rat will
get 5 trials and testing will occur on days 0, 1,7, 14, and 21, where day 0 is before the procedure.
8

Optic Nerve Crush Surgical Procedures
All of the surgical procedures used were approved by the Northeast Ohio Medical
University IACUC and were performed aseptically. All personal wore sterile gloves and masks
and instruments were sterilized and cleaned using 70% ethanol before surgeries. In between
surgeries, a glass bead sterilizer was used to clean the instruments. Rats were anesthetized with
isoflurane and were given a subcutaneous injection of ketoprofen before surgery for pain.
Anesthetic was applied to the cornea. Using an operating microscope and small iridectomy
scissors, a lateral canthotomy was performed, followed by a dissection of the conjunctiva of the
right eye. The globe was rotated nasally using 9-0 conjunctival suture and tweezers to expose the
optic nerve. The optic nerve was then subjected to a mild crush injury 2 mm from the globe using
a micro-vascular clip that was held for 10 seconds. The 2mm chitosan tube treatments were cut
into thirds, such that the wrap was 2mmx4mm. The tubes were placed on one side of the optic
nerve and then cuffed at the top and bottom to wrap around the nerve. A biocompatible fibrin
sealant was used to hold the tube in place. The eye was rotated back into place and the conjunctiva
was laid back into place. One stitch of 10-0 absorbable suture was used to close the canthotomy.
RGC Labeling
On day 18, cholera toxin B (CTB) conjugated with AlexaFluor 488 was intravitreally
injected. The tracer labeled the RGCs. The rats were anesthetized with isoflurane, and
proparacaine hydrochloride was applied to the cornea. A 33G hyprodermic needle was used to
inject 3µL of the marker into the eye.
Tissue Isolation and Immunohistochemistry Analysis
On day 21, an intra-cardiac perfusion with formaldehyde fixation was performed after an
overdose of sodium pentobarbital. After the perfusion, the eyes, optic nerves and brain were
isolated and stored in 0.1 PBS with sodium azide. The optic nerves will be isolated from the eyes
and sectioned longwise on a sliding microtome with a cooling stage. The sections were mounted
and imaged with a fluorescent microscope. To quantify the images, the intensity of the CTB marker
was measured before and after the crush site and the ratio will be used to quantitatively compare
the different treatment groups.
Statistical Analysis
A two factor analysis of variance (ANOVA) was performed with Minitab software for the
behavioral analysis and the CTB marker intensity ratio data. These data are reported as mean ±
standard deviation (SD). Significance was established with an α level of 0.05.
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Figure 2: The figure above shows demonstrates the surgical procedure used for the optic nerve
crush. (A) After the canthotomy, sutures through the conjunctive were used to rotate the globe
nasally. (B) Forceps were used to expose the optic nerve. (C) The chitosan or MAC(Ali15)F tube
treatments were places around the optic nerve. (D) After placing the fibrin glue sealant and rotating
the globe back into place, a single suture was used to close the canthotomy. Note that these pictures
were from practice surgeries with cadaver rats, and that the eyes have been moved to further expose
the optic nerve for demonstration purposes. In the actual surgeries, the optic nerve was not exposed
as grossly and the treatments did not wrap all of the way around the optic nerve. (McCormick,
2014).

Results and Discussion
bNGF Protein Release from Chitosan Tubes
The release of bNGD in vitro was evaluated over 21 days in 0.1M PBS. Samples were
extracted from chitosan tube samples containing ImmbNGF. The total bound protein would be
38ng, given that 100 L of 1,000 ng/mL solution was added to each tube and bNGF has a 38%
binding efficiency (McCormick et. al., 2013). The total release of bNGF from the ImmbNGF
10

chitosan tubes at day 21 was 630±160 pg. This is less then 2% of the total protein in the tube, so
the majority was not released in to the PBS, shown in Figure 3. This indicates that the majority of
the protein remains attached to the chitosan substrate. This was suspected, considering that the
bNGF is covalently bonded with the chitosan.
In a study completed by Mey and Thanos, 1992, a dosage of 50 ng of different growth
factors was injected intravitreally to promote RGC survival after the transection of the optic nerve.
The dosage delivered by the ImmbNGF chitosan tube was significantly lower than this study,
however the amount of protein present at the injection site at the end of the experiment was not
quantified so a direct comparison cannot be made. The downside of the injection method is that
the effects were short term, thus multiple injections were required to see long term RGC survival.
The need for a sustained delivery directly to the injury site is still needed. In addition to
immobilized protein applications, soluble protein treatments should be considered to maximize
protein delivery to the injury site.

Figure 3: The figure above was adapted from a previous work about the same study
(McCormick, 2014). The cumulative bNGF release from ImmbNGF (listed as ImNGF in the
figure) chitosan tubes was measured over 21 days, shown by the solid line. Very little protein
was released compared to the total amount of protein immobilized on the chitosan, shown by the
dotted line. The MixNGF and Mix+ImNGF included soluble NGF in the material, however it
was later discovered that an error in the material preparation would have degraded all of the
soluble protein, which is why those two groups were not considered for this work. The mean ±
standard deviation of the cumulative bNGF release is plotted, n=6.
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Behavioral Analysis
The visual depth perception of the rats was evaluated using the cage drop method described
in the Materials and Methods , where the distance at which rats were able to recognize the top of
a cage when lowered towards was measured. This was performed was measured before and after
the ONC procedures on days 0 (before procedure), 1, 7, 14, and 21. The results of the cage drop
testing are shown in Figure 4A. For this type of behavioral analysis, it is critical to establish a base
line prior to the start of the experiment so any changes after the experiment can be properly
evaluated. The was only a significant difference between the Chitosan Tube group on days 0 and
, indicating that a true base line was not established because there is not a significant difference
between day 0 and day 1 for all groups. Many other factors could have affected the results of this
test. Inflammation, infection, and irritation of the surgical area could have influenced the results
in addition to the injury itself. In addition, the amount of handling and the individual performance
of the rats could have affects the results. Figure 4B-E shows the trends for the individual rats in
the study. In general, there is a decrease from day 0 to day 1, and a general increase from day 1
forward, but it is not consistent for each rat. For example, three rats in the Chitosan Tube group
showed a significant change between day 0 and day 1 and a steady increase in performance up to
day 14. These three rats in particular were part of the preliminary study and experienced greater
handling than the other rats in the study, which may explain why their results are more pronounced.
To truly determine the impact of the injury and the different treatments, the further analysis of the
tube placements, crush severity, and RGC health is required. In the future, other types of more
established methods of assessing visual acuity, such as cliff test and the water box test, should be
considered (Fox, 1965; Prusky et. al., 2000).
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Figure 4: The figure above shows the cage drop test results that were used to access the visual
acuity of the rats before and after the ONC. (A) The mean height ± standard deviation for the cage
were the rats reached out is shown for each treatment group on days 0, 1, 7, 14, and 21m where
day 0 is before the ONC procedure. The error bars show the standard deviation. The * indicates a
statistically significant difference between those groups determined by two-factor ANOVA. (B-E)
The performance of individual rats was plotted for each group to show the differences in how each
rat responded to the test. Each line represents an individual rat. The sample size for all groups was
n=6 except for MAC(Ali15)F, which was n=5.
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ONC Model Execution and Tissue Isolation
After day 21, the eyes and optic nerves both the right and left eyes of each rat were isolated.
During the tissue isolation, the placement of the chitosan and MAC(Ali15)F tubes was evaluated.
Correct tube placement was only observed 50% of the time, show in Figure 5A. It is believed that
when the eye was rotated back into position that the tube would shift out of place, causing it to lie
on the back of the globe, as shown in Figure 5B. This indicates that a change in the tube design is
required. It is possible that a tube with a smaller diameter would stay in place better. In addition
to the tube placement, the actual crush site was evaluated. Only 28% of the rats had a crush site
that was visible through the dissection microscope. From the fluorescent microscopy performed
on the sectioned optic nerves (discussed further later), only 39% of the rats showed evidence of a
crush injury. This indicated that the surgical tools and procedures needs improvement in order to
have a consistent injury every time. Traditionally, tweezers are used to inflict the crush injury
(Tang et. al., 2011; Templeton et. al., 2012), but consistent pressure for each injury was a concern.
It was thought that using a micro-vascular clip would standardize the amount of pressure applied
for each crush injury, however, due to the other tissue around the optic nerve, it was difficult to
place the clip during the procedure. This could be improved with more practice, or the employment
of a surgeon. In addition, other injury models such as the optic nerve stretch model where the optic
nerve is mechanically stretched to induce an injury. This type of injury can be less severe than a
crush or transection injury, thus allowing one to investigate a mild injury, which is more common
in humans (Maxwell et. al., 1994).

Figure 5: The images above show eyes and optic nerves used to analyze the treatment tube
placement. (A) The tube placement was in the correct location on the ONC site. (B) The tube was
shifted after placement and stuck to the back of the globe of the eye. (C) After dissection, the optic
nerves were separated from the eye and cleaned. ONC sites could be identified by the discoloring
on the never approximately 2 mm away from the eye. The arrows designate either the tube (A-B)
or the crush site (C). (McCormick, 2014).
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CTB Intensity Analysis
On day 18 of the study, both the right and left eyes were injected with CTB to label the
axon tracks in the optic nerve. After isolation, optic nerves were sectioned, mounted, and imaged
using a fluorescent microscope. Figure 6A-B shows a comparison of the right and left optic nerves.
The crush site is evident in Figure 6B not only by the narrowing of the optic nerve, but the bright
spotting of CTB, which was evident in most of the confirmed crush sites. In addition to the CTB,
GFAP was used to study the astrocyte expression in the optic nerve. As shown in Figure 6C-D,
the uninjured left optic nerve shows very little astrocyte expression, where there is high expression
on the injured optic nerve, especial around the crush site. This verifies that astrogliosis is occurring,
where reactive astrocytes increase, confirming that an injury occurred.
Using ImageJ software, the intensity of the CTB staining in a region of interest, like the
ones shown in Figure 6A-B, was quantified before and after the crush. The ratio of the post-crush
and pre-crush CTB intensity were used to compare each treatment group to the left, uninjured,
optic nerves. The results are show in Figure 7. Using two way ANOVA, it was shown that there
was a statically significant difference between the intensity ratio of the right and left optic nerves.
This indicates that an injury was inflicted to the right optic nerves and it was detectable by the
CTB intensity. However, there was no statistical significant difference between the different
treatment groups and the crush with no treatment.
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Figure 6: The images above show the longitudinal sections of injured and non-injured (sham)
optic nerves with CTB labeling and astrocyte activation and distribution. (A-B) An example of a
region of interest is shown after the crush site. This region of interest was used to measure the
intensity of the CTB labeling. The microscope image settings and expose were kept constant to
ensure the intensities were comparable. (C-D) Astrocyte expression was evaluated using a GFAP
label. (C) shows minimal expression where (D) shows much higher astrocyte expression,
especially around the crush site indicating that there was a response to the injury. Like (A-B), (CD) were imaged using the same microscope parameters so the intensity could be compared. Scale
bar = 100 m. (McCormick, 2014). The arrows on (B) and (D) indicate the crush sites.
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Figure 7: The mean ± standard deviation of the ratio of CTB intensity before and after the crush
site was determine for both the right and left optic nerves of the rats in each treatment group. The
right optic nerves were subjected to the ONC, and the left serve as a control. The crush group
received the injury, but no treatment. The * indicates a statistically significant difference by two
way ANOVA. For all groups the sample size was n=6, apart from MAC(Ali15)F which was n=5.
Conclusions
Two different treatment methods were employed to the ONC model through this study.
One where NGF was immobilized to a chitosan substrate in an attempt to stimulate axonal
regeneration, and the other made from MAC(Ali15)F was used in an attempt to promote a healing
environment. From the ratio of CTB intensity results, it is clear that an injury was created, however,
there was no difference between the treatments and the untreated injured optic nerve. Since the
crush injuries were difficult to identify visually, it indicates that the injury itself may not have been
severe enough to detect a difference between the treatments. Using a more severe injury model
could have improved the efficacy of the treatment by making the difference between the treatments
more discernable. In addition, the rat model may not have been the most appropriate choice since
the rat optic nerve does not have the central retinal artery, like a human’s does. A rabbit model
may be more appropriate since its optic nerve anatomy is more similar to the human’s (Gwon,
2008). The surgical model can also be improved by either adjusting the tools and techniques used
for the optic nerve crush, or by selecting a model that is easier to control, such as the optic nerve
stretch model (Maxwell et. al., 1994). In addition, the treatments could be improved by integrating
a soluble protein to increase the dosage to the injury site, or by incorporating more than other
neural guidance molecules in addition to NGF (Mey et. Al., 1992). Previous works have shown
NGF’s ability to guide axonal growth, however MAC(Ali15)F has not. In order to determine the
efficacy of MAC(Ali15)F used for neural regeneration, in vitro experiments should be performed
17

so that all external variables are controlled and the impact of MAC(Ali15)F alone can be assessed.
Since MAC(Ali15)F was formulated for external wound treatments, other additional preparations,
such as oxygen recharging, may be required for it to aid in the treatment of an internal injury.
Other delivery methods like the injection of the hydrogel should also be considered. This may
better ensure the correct placement of the treatment and would be less invasive when applied to a
pre-existing injury. This work has highlighted key areas that need further understanding and
investigation in order to develop an effective biomaterial treatment of central nervous system
injuries, especially optic nerve sparing or regeneration.
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